How can the current forecast not include XPerience, it...

First 54 Last

Share
Profile

Follow
Tarvold

18,104 Posts.

1195

19/06/21

17:18

Post #: 53943935
Share

Originally posted by MikeMelb1969: ↑

Clarification of a few issues relating to the H1 Revenue update. (My interpretation)

Considering the announcement in isolation - it makes for horrible reading, is vague, ambiguous and disingenuous and left me concerned. I sent a scathing email to the company management listing my concerns and dissatisfaction. To their credit, I received a detailed response and had the opportunity to engage.

Bottom line - Next Science policy as regards revenue, is to recognise on delivery to their customer (in the customers hands! The policy is disclosed in their financial accounts). They were made aware at the back end of last week, that an order due for delivery to Zimmer (from their manufacture facility in Mexico) would not in fact be received by Zimmer until the beginning of Q3. I assume this was a significant order and part of the multi-year agreement between Next Science and Zimmer. This is purely a timing issue but would affect Q2 negatively (and consequently Q3 positively).

The original guidance to which this update referred did not consider the possible impact of Xperience revenue (given that FDA approval had not yet been received) and so this updated guidance also does not include the possible impact of Xperience revenue.

Expand

How can the current forecast not include XPerience, it specifically states what the expected total revenue will be for H1?
Yes the prior forecast did not include XPerience because the approval wasn't certain but that makes the reduction even worse because the current one does.

Why didn't they disclose why the forecast was cut & that it was only a timing difference?
Sounds like BS to me.

NXS Price at posting: $1.51 Sentiment: None Disclosure: Not Held
2 Upvote

1 Great analysis

Reply